
Feb 17 (Reuters) - Compass Pathways PLC CMPS.O:
COMPASS PATHWAYS SUCCESSFULLY ACHIEVES PRIMARY ENDPOINT IN SECOND PHASE 3 TRIAL EVALUATING COMP360 PSILOCYBIN FOR TREATMENT-RESISTANT DEPRESSION
COMPASS PATHWAYS PLC - COMP360 SHOWS WELL-TOLERATED AND SAFE PROFILE
COMPASS PATHWAYS PLC - REQUESTS FDA MEETING FOR ROLLING SUBMISSION